Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
65

Summary

Conditions
  • Breast Cancer
  • Acral Lentiginous Melanoma
  • Colorectal Cancer
  • DMMR Colorectal Cancer
  • Esophageal Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Hepatocellular Carcinoma
  • Melanoma
  • Urothelial Carcinoma
  • MSI-H Colorectal Cancer
  • Non -Small Cell Lung Cancer
  • Ovarian Cancer
Type
Interventional
Phase
Phase 1
Design
Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

For the ATRC-101 monotherapy cohorts, enrollment is restricted to adults with breast cancer (BC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer, and acral melanoma. For the pembrolizumab combination therapy cohort, enrollment is restricted to adults with NSCLC, CRC (onl...

For the ATRC-101 monotherapy cohorts, enrollment is restricted to adults with breast cancer (BC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer, and acral melanoma. For the pembrolizumab combination therapy cohort, enrollment is restricted to adults with NSCLC, CRC (only MSI-H or dMMR), melanoma (with the exception of uveal melanoma), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), or urothelial carcinoma (UC), that have been treated with pembrolizumab and have progressed or have achieved stable disease and who, in the judgment of their treating physicians, could benefit from the addition of ATRC-101 to improve or maintain their response.

Tracking Information

NCT #
NCT04244552
Collaborators
Not Provided
Investigators
Study Director: Jonathan Benjamin, MD, PhD Atreca, Inc.